The ongoing epidemic of cholera in Haiti is one of the largest of the last decade and is representative of a growing burden of epidemic cholera. Remarkably little is known about immune responses to cholera and oral cholera vaccines in immunologically na?ve populations, and in populations outside of historically cholera endemic areas of Asia. Of paramount importance, all decisions regarding the use of cholera vaccine have been made using immunogenicity and efficacy data generated in areas of the world where cholera has long been entrenched and where cholera vaccine may be boosting anamnestic immune responses in previously exposed individuals. Therefore, assessment of vaccine immunogenicity and effectiveness during the roll out of Shanchol in Haiti provides the unique opportunity to directly inform vaccine strategies. Almost nothing is known about the relationship between HIV and cholera, despite the fact that the largest number of cholera cases reported to WHO are now from Sub-Saharan Africa. Here, we propose to characterize immune responses to oral cholera vaccines and to V. cholerae infection in Haiti -- a previously immunologically na?ve population with host and epidemiologic features that are reflective of populations experiencing cholera epidemics in recent years. We also directly assess the efficacy of the oral cholera vaccine, Shanchol, in Haiti, and evaluate the inter-relationship between HIV and V. cholerae infection and vaccination. Our collaborative team is deeply involved in the cholera vaccine roll-out in Haiti and is uniquely situated to perform the proposed studies.
Understanding immune responses to Vibrio cholerae vaccination and infection, and assessing vaccine effectiveness in Haiti, will directly aid our understanding of how best to utilize cholera vaccines in Haiti and in future cholera epidemics.
|Mayo-Smith, Leslie M; Simon, Jakub K; Chen, Wilbur H et al. (2017) The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae. Clin Vaccine Immunol 24:|
|Franke, Molly F; Jerome, J Gregory; Matias, Wilfredo R et al. (2017) Comparison of two control groups for estimation of oral cholera vaccine effectiveness using a case-control study design. Vaccine 35:5819-5827|
|Matias, Wilfredo R; Teng, Jessica E; Hilaire, Isabelle J et al. (2017) Household and Individual Risk Factors for Cholera among Cholera Vaccine Recipients in Rural Haiti. Am J Trop Med Hyg 97:436-442|
|Levade, Inès; Terrat, Yves; Leducq, Jean-Baptiste et al. (2017) Vibrio cholerae genomic diversity within and between patients. Microb Genom 3:|
|Kauffman, Robert C; Bhuiyan, Taufiqur R; Nakajima, Rie et al. (2016) Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells. MBio 7:|
|Matias, Wilfredo R; Falkard, Brie; Charles, Richelle C et al. (2016) Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults. PLoS Negl Trop Dis 10:e0004753|
|Harris, Jason B; LaRocque, Regina C (2016) Cholera and ABO Blood Group: Understanding an Ancient Association. Am J Trop Med Hyg 95:263-4|
|Koski-Karell, Victoria; Farmer, Paul E; Isaac, Benito et al. (2016) Haiti's progress in achieving its 10-year plan to eliminate cholera: hidden sickness cannot be cured. Risk Manag Healthc Policy 9:87-100|
|Ivers, Louise C; Hilaire, Isabelle J; Teng, Jessica E et al. (2015) Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. Lancet Glob Health 3:e162-8|
|Ellis, Crystal N; LaRocque, Regina C; Uddin, Taher et al. (2015) Comparative proteomic analysis reveals activation of mucosal innate immune signaling pathways during cholera. Infect Immun 83:1089-103|
Showing the most recent 10 out of 25 publications